Lotilaner ophthalmic not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days”In the company’s words, NCT06182358 on ClinicalTrials.gov
- Tested for
- Demodex Blepharitis
- Main trialPhase 4
- “To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.”In the company’s words, NCT06182358 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | 27 Jan 2025 | Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026